EUCTR2006-004014-41-SE进行中（未招募）不适用
A randomised, single-blind, placebo-controlled study to investigate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of intravenous infusion of GSK933776A in patients with Alzheimer’s disease
GlaxoSmithKline Research and Development0 个研究点目标入组 122 人开始时间: 2006年10月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 122
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female subject with mild Alzheimer's Disease (AD) with MMSE score 18-26 inclusive at the screening visit.
- •2. Age 55 to = 80 years
- •3. Females must be post-menopausal (i.e. >24 months without menstrual period) or surgically sterile. Female subjects who have been post-menopausal for < 2 years must undertake pregnancy testing (ßhCG) at Visit 1, which must be negative and must use an adequate form of non-hormonal contraceptive (e.g. barrier method).
- •4. Males whose partner is of child-bearing potential or have been menopausal for <2 years must use an adequate form of contraception (e.g. barrier method).
- •5. Subject has the ability to comply with procedures for cognitive and other testing, including MRI scans, and is fluent in the language used for the administration of the cognitive tests.
- •6. Subject lives with (or has substantial periods of contact with) a permanent caregiver who is willing to oversee the subject's compliance with protocol-specified procedures and study medication, and report on subject's status.
- •7. Fluency in local language and evidence of adequate pre-morbid intellectual functioning. Subject must have adequate visual and auditory abilities to perform all aspects of the cognitive and functional assessments.
- •8. In the opinion of the Investigator, the subject and the caregiver will be compliant and have a high probability of completing the study.
- •9. Subject has provided full written informed consent prior to the performance of any protocol-specified procedure.
- •10. Caregiver has provided a full written informed consent on his/her own behalf prior to the performance of any protocol-specified procedure.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. History and/or evidence of any other central nervous system (CNS) disorder that could be interpreted as a cause of dementia
- •2. Hachinski Ischaemia Score >4
- •3. Subjects currently living in a nursing home.
- •4. Subjects who are unable to provide informed consent due to cognitive status
- •5. Screening brain MRI with one or more of the following conditions:
- •a) not consistent with AD
- •b) has evidence of other CNS conditions listed in criterion 1
- •c) shows more than minimal vascular changes
- •d) shows more than 3 microhaemorrage lesions
- •6. Focal findings on the neurological exam (excluding changes attributable to peripheral injury or AD).
- •7. Untreated abnormal result of any of the following tests: vitamin B12, syphilis serology, thyroid stimulating hormone (TSH), where this is thought to be the cause of, or to contribute to the severity of, the subject’s dementia.
- •8. Any contraindications to lumbar puncture.
- •9. History or evidence of significant psychiatric illness such as schizophrenia or bipolar affective disorder or significant neurological disease other than AD, including epilepsy, that in the opinion of the Investigator may affect cognition or would interfere with participation in the study, or Hamilton Psychiatric Rating Scale for Depression (HAM D) (17 item) score >12.
- •10. TIA/stroke in the last 3 years, type 1 or type 2 diabetes mellitus, active cardiovascular disease or other uncontrolled risk factors for stroke.
- •11. History or evidence of any significant autoimmune disease or disorder.
- •12. History of seizures (excluding febrile seizures in childhood), current blood clotting or bleeding disorder or conditions that predispose to these, current clinically significant systemic illness or significant infection within 30 days (e.g. chronic persistent or acute infection).
- •13. Treatment with cholinesterase inhibitors is prohibited unless therapy was instituted at least 3 months prior to the administration of GSK933776A, was at stable dosage in the 2 months preceding, subject is free from any clinically significant side effects attributable to the drug that, in the opinion of the investigator, would preclude participation in the trial and that subject and caregiver agree that, barring unforeseen circumstances, the same regimen will be continued for the duration of the trial.
- •14. Subjects who have discontinued cholinesterase inhibitors, memantine, cognitive enhancing agents, or drugs that potentially affect cognition in the 60 days prior to screening.
- •15. Unless maintained on a stable dose regimen for at least 30 days prior to screening, any other medications with the potential to affect cognition other than those mentioned in #13.A single dose of a short acting benzodiazepine is allowed at MRI and PET screening provided that the dose is given more than 24 hours before cognitive testing.
- •16. Use of drugs with platelet antiaggregant or anti-coagulant properties (excluding the use of aspirin 325 mg/day or less
- •18. History of or current chronic use of systemic steroids or other immunosuppressants.
- •19. Prior participation in clinical investigations involving therapeutic monoclonal antibodies or proteins derived from monoclonal antibodies or any investigations of treatments or use of experimental medications for AD or any other investigational medication or device within 60 days prior to screening or within 5 half-lives of use of such a medication prior to screening, whichever is longer.
- •20. Systolic blood pressure >165 mmHg or d
研究者
相似试验
招募中
不适用
To evaluate the efficacy andsafety of Nigellin in individuals with allergic rhinitisCTRI/2022/07/044180Sami Sabinsa Group Limited
已完成
Unknown
Acute effects of hibiscus sabdariffa on cardiometabolic markers and cognitive functioReduction of blood pressureCirculatory SystemISRCTN14881129niversity of Leeds20
进行中（未招募）
Unknown
A study to evaluate the use of a cholera vaccine as an immune challenge for the mucosal immune systemOral cholera vaccination with intranasal rechallenge as an adaptive immune challenge modelISRCTN14583662Centre for Human Drug Research16
已完成
不适用
A randomized, single-blind, placebo-controlled study to evaluate an oral cholera vaccination with intranasal rechallenge as adaptive immune challenge modelThere will be no specific condition investigated in this study10004018NL-OMON53390Centre for Human Drug Research12
进行中（未招募）
1 期
A study in healthy volunteers who have first been given respiratory syncytial virus (RSV), looking at the effect of repeat doses of a new drug called PC786, compared with placebo (a dummy drug), on safety and levels of the drug in the blood after it has been inhaled twice a day for up to 5 daysHuman Respiratory Syncytial Virus (RSV)MedDRA version: 20.0 Level: LLT Classification code 10070358 Term: Human respiratory syncytial virus test positive System Organ Class: 100000109842EUCTR2017-002563-18-GBPulmocide Ltd56